EUSA Pharma announce acquisition of SYLVANT® from Janssen

EUSA Pharma acquires SYLVANT from Janssen for $115 million

BioIVT acquires Optivia Biotechnology

BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its...

Sanofi and Advent finalise negotiations for the acquisition of Zentiva

Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva - Sanofi's European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion...

Takeda ups bid to $65 billion in negotiations to buy Shire

Takeda has increased offer to buy Shire for a mix of stock and cash worth ~$65 billion

Merck to sell Consumer Health to Procter & Gamble

Merck has sold its global Consumer Health business to Procter & Gamble

Advent in negotiations to acquire Sanofi’s generics business

Advent and Sanofi are in negotiations under which Advent would acquire Zentiva,

Certara acquires Analytica Laser

Certara announced it has acquired Analytica Laser which uses health economics and outcomes research (HEOR)

Mylan partners with Fujifilm Kyowa Kirin Biologics

Mylan partners with Fujifilm Kyowa Kirin Biologics to commercialise a biosimilar to Humira®

GSK buys out Novartis’ stake in Consumer Healthcare

GlaxoSmithKline plc have announced that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint...

Nanologica & Sterling partnership furthers new business venture

Nanologica AB has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production of...

Latest articles

Image of four people communicating via different mediums to depict mind the Generation Gap in pharma marketing

Mind the Generation Gap in pharma marketing and market research

Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents results from Phase III TULIP 2 trial for anifrolumab

AstraZeneca presents anifrolumab results from Phase III TULIP trial

Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...

Popular articles

People sitting around a desk with laptops and tablets to show NHS Commercial Framework for Medicines published for consultation

NHS Commercial Framework for Medicines consultation published

NHS England has published the NHS Commercial Framework for Medicines for consultation. NHS England has a significant role to play in supporting patient access to...
Mapping NHS change is key to customer engagement

Mapping NHS change is key to customer engagement

Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
Pharmafield logo in lightbulb: Pf Power List 2019

Pf Power List 2019: Who is shaping the pharma & healthcare sector?

The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019. This year has brought a range of developments...
Image of a head with squiggly lines in the brain and cogs on top to indicate Medopad and Janssen collaborate on novel digital biomarker for Alzheimer's disease

Medopad and Janssen collaborate on novel digital biomarker for Alzheimer’s disease

Medopad has announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription